News

Back

TheraVet raises 4 M€ to accelerate the development of its two veterinary products

December 10th 2020

BioPark

TheraVet S.A., announced today that it will raise by the end of 2020 €4 million of additional funding for the development of its innovative veterinary product lines. This funding consists of a capital increase of €1.9 million realized with TheraVet’s historical shareholders which include: the fund Theodorus III, the fund Innovation Fund, the regional investment funds Financière Spin-Off Luxembourgeoise and the Luxembourg Développement Europe 2 and Business Angels. Please discover the press release here.